TY - JOUR
T1 - Carboplatin (CBDCA) plus ifosfamide (IFO) as first-line chemotherapy in advanced (FIGO III and IV) ovarian cancer
T2 - A pilot study
AU - Brandi, Mario
AU - De Mitrio, Alessandra
AU - Lorusso, Vito
AU - Gargano, Giulio
AU - Caporusso, Luciana
AU - Leone, Bernardo
AU - Rabinovich, Mario
AU - Cataldi, Antonella
AU - Fioretto, Antonio
AU - De Lena, Mario
PY - 1997/3
Y1 - 1997/3
N2 - A phase II study of advanced FIGO III and IV ovarian cancer treated with carboplatin and ifosfamide was performed to define the efficacy and tolerability of this regimen as first-line chemotherapy. From November 1990 to December 1994, 30 women with advanced ovarian cancer or residual disease after initial surgery were treated with carboplatin (300 mg/m2 intravenously on day 1) and ifosfamide (1,500 mg/m2 intravenously on days 1-3, with MESNA) every 3 weeks. The overall response rate was 67% (complete response 27%, partial response 40%) and the median duration of response was 14 months (range, 6-36). After a median follow-up of 31 months, the median survival was 24.9 months. Time to progression (p <0.05) and overall survival were longer in the patient group subjected to debulking. This regimen was easily manageable with good activity and acceptable toxicity, and most patients were treated on an outpatient basis.
AB - A phase II study of advanced FIGO III and IV ovarian cancer treated with carboplatin and ifosfamide was performed to define the efficacy and tolerability of this regimen as first-line chemotherapy. From November 1990 to December 1994, 30 women with advanced ovarian cancer or residual disease after initial surgery were treated with carboplatin (300 mg/m2 intravenously on day 1) and ifosfamide (1,500 mg/m2 intravenously on days 1-3, with MESNA) every 3 weeks. The overall response rate was 67% (complete response 27%, partial response 40%) and the median duration of response was 14 months (range, 6-36). After a median follow-up of 31 months, the median survival was 24.9 months. Time to progression (p <0.05) and overall survival were longer in the patient group subjected to debulking. This regimen was easily manageable with good activity and acceptable toxicity, and most patients were treated on an outpatient basis.
KW - carboplatin
KW - ifosfamide
KW - ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=12644302231&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=12644302231&partnerID=8YFLogxK
M3 - Article
C2 - 21533405
AN - SCOPUS:12644302231
VL - 10
SP - 509
EP - 514
JO - International Journal of Oncology
JF - International Journal of Oncology
SN - 1019-6439
IS - 3
ER -